Sign In
Buy XNCR
$20.21
-1.28 (-5.96%)
At Close: Jul 31, 2026
Xencor, Inc. (NASDAQ:XNCR) Receives $53.50 Consensus Target Price from Brokerages
03:58pm, Friday, 19'th Nov 2021 Dakota Financial News
Xencor, Inc. (NASDAQ:XNCR) has earned an average recommendation of Buy from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price []
Credit Suisse AG Sells 6,333 Shares of Xencor, Inc. (NASDAQ:XNCR)
10:54am, Wednesday, 17'th Nov 2021 Dakota Financial News
Credit Suisse AG lessened its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 8.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,657 shares of the biopharmaceutical companys stock after selling 6,333 shares during the quarter. Credit Suisse AGs holdings in Xencor []
Analysts Issue Forecasts for Xencor, Inc.s FY2021 Earnings (NASDAQ:XNCR)
06:52am, Sunday, 14'th Nov 2021 Transcript Daily
Xencor, Inc. (NASDAQ:XNCR) Research analysts at SVB Leerink increased their FY2021 earnings per share (EPS) estimates for shares of Xencor in a research report issued to clients and investors on Tuesday, November 9th. SVB Leerink analyst J. Chang now forecasts that the biopharmaceutical company will post earnings of $0.94 per share for the year, []
Xencor's (XNCR) CEO Bassil Dahiyat on Q3 2021 Results - Earnings Call Transcript
08:27pm, Monday, 08'th Nov 2021
Xencor's (XNCR) CEO Bassil Dahiyat on Q3 2021 Results - Earnings Call Transcript
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
06:23pm, Monday, 08'th Nov 2021
Xencor (XNCR) delivered earnings and revenue surprises of 8.00% and 11.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
4 Small Drug Stocks That Hold Promise Despite Industry Challenges
09:05am, Wednesday, 27'th Oct 2021
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.
Wall Street Analysts See a 55% Upside in Xencor (XNCR): Can the Stock Really Move This High?
01:50pm, Monday, 11'th Oct 2021
The consensus price target hints at a 55.4% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Xencor (XNCR) Upgraded to Strong Buy: Here's Why
02:30pm, Thursday, 07'th Oct 2021
Xencor (XNCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody
10:26am, Monday, 04'th Oct 2021
Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global licensing rights with Xencor Inc (NASDAQ: XNCR).
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
08:01am, Friday, 01'st Oct 2021
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and auto
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q2 2021 Results - Earnings Call Transcript
12:10am, Thursday, 05'th Aug 2021
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q2 2021 Results - Earnings Call Transcript
Xencor (XNCR) Q2 Earnings and Revenues Surpass Estimates
07:04pm, Wednesday, 04'th Aug 2021
Xencor (XNCR) delivered earnings and revenue surprises of 242.62% and 296.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
04:01pm, Wednesday, 28'th Jul 2021
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and aut
Down 10.9% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround
11:30am, Tuesday, 27'th Jul 2021
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021
07:01am, Friday, 23'rd Jul 2021
These biotech stocks could have great long-term potential.
